Shield Therapeutics PLC Annual Report, Accounts and AGM Notification (6133D)
April 28 2017 - 1:00AM
UK Regulatory
TIDMSTX TIDMSTXW
RNS Number : 6133D
Shield Therapeutics PLC
28 April 2017
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
2016 Annual Report and Accounts and 2017 AGM Notification
London, UK, 28 April 2017. Shield Therapeutics plc (LSE:STX), a
specialty pharmaceutical Company focused on secondary care, gives
notice that copies of its 2016 Annual Report and Accounts have been
sent to shareholders. This document is available on the "Investors"
section of the Company's website at www.shieldtherapeutics.com.
Shield announced preliminary results for the year ended 31 December
2016 on 4 April 2017.
Further copies of the Annual Report will be available from the
Company Secretary, Shield Therapeutics plc, Northern Design Centre,
Baltic Business Quarter, Gateshead Quays, NE8 3DF.
Shield also announces that its Annual General Meeting will be
held on 13 June 2017. The meeting will be held at Stephenson
Harwood LLP, 1 Finsbury Circus, London EC2M 7SH, commencing at 2.00
pm. Notice of the Annual General Meeting has been sent to
shareholders on Friday 28 April 2017.
- Ends -
For further information please contact:
Shield Therapeutics plc +44 (0)207 186 8500
Carl Sterritt, Chief Executive
Officer
NOMAD
Liberum Capital Limited
Christopher Britton/Steve
Pearce +44 (0)20 3100 2222
Financial PR Advisor +44 (0)203 709 5700
Consilium Strategic Communications shieldtherapeutics@consilium-comms.com
Mary-Jane Elliott/Matthew
Neal/Lindsey Neville/Hendrik
Thys
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company
focused on the commercialisation and development of late-stage,
hospital-focused pharmaceuticals which address areas of unmet
medical need. Our clear purpose is to help our patients become
people again, by enabling them to enjoy the things that make the
difference in their everyday lives. The Group has a marketed
product, Feraccru(R), for the treatment of iron deficiency anaemia
(IDA) in adult patients with inflammatory bowel disease (IBD) which
has exclusive IP rights until the mid-2030's. In addition, the
Group is developing PT20, a late-stage pharmaceutical for the
treatment of systemic phosphate accumulation (hyperphosphatemia).
Shield Therapeutics, headquartered in London, is listed on LSE's
AIM under the ticker STX. For more information please visit
www.shieldtherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSEAFMWFWSESL
(END) Dow Jones Newswires
April 28, 2017 02:00 ET (06:00 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2024 to May 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From May 2023 to May 2024